1-Aryl-3-(4-methoxybenzyl)ureas as potentially irreversible glycogen synthase kinase 3 inhibitors: Synthesis and biological evaluation
Abstract
Glycogen synthase kinase 3 (GSK-3) has become known for its multifactorial involvement in the pathogenesis of Alzheimer's disease. In this study, a benzothiazole- and benzimidazole set of 1-aryl-3 (4-methoxybenzyl)ureas were synthesised as proposed Cys199-targeted covalent inhibitors of GSK-3 beta, through the incorporation of an electrophilic warhead onto their ring scaffolds. The nitrile-substituted benzimidazolylurea 2b (IC50 = 0.086 +/- 0.023 mu M) and halomethylketone-substituted benzimidazolylurea 9b (IC50 = 0.13 +/- 0.060 mu M) displayed high GSK-3 beta inhibitory activity, in comparison to reference inhibitor AR-A014418 (1, IC50 = 0.072 +/- 0.043) in our assay. The results suggest further investigation of 2b and 9b as potential covalent inhibitors of GSK-3 beta, since a targeted interaction might provide improved kinase-selectivity.
Más información
Título según WOS: | ID WOS:000468145300009 Not found in local WOS DB |
Título de la Revista: | BIOORGANIC MEDICINAL CHEMISTRY LETTERS |
Volumen: | 29 |
Número: | 13 |
Editorial: | PERGAMON-ELSEVIER SCIENCE LTD |
Fecha de publicación: | 2019 |
Página de inicio: | 1597 |
Página final: | 1600 |
DOI: |
10.1016/j.bmcl.2019.04.049 |
Notas: | ISI |